Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392326 · ClinicalTrials.gov registry record · Phase 3
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
A Phase 3 study of Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
- 20
- Study locations
NCT01392326 is a Phase 3 study of Psoriatic Arthritis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 606 participants, below the 840-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT01392326, a Phase 3 study of Psoriatic Arthritis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG Secukinumab (75 mg)
- DRUG Secukinumab (150 mg)
Study Locations (20)
Arizona
- Novartis Investigative Site - Mesa
- Novartis Investigative Site - Paradise Valley
South Carolina
- Novartis Investigative Site - Columbia
- Novartis Investigative Site - North Charleston
Texas
- Novartis Investigative Site - Benbrook
- Novartis Investigative Site - Dallas
Alabama
- Novartis Investigative Site - Anniston
California
- Novartis Investigative Site - Upland
Florida
- Novartis Investigative Site - Tamarac
Georgia
- Novartis Investigative Site - Newnan
Massachusetts
- Novartis Investigative Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01392326
The ClinicalTrials.gov registry entry for NCT01392326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 840-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (28% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT01392326 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Arizona, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT01392326 about?
NCT01392326 is a clinical study titled "Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)". This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
What is the current status of trial NCT01392326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2011-09. Estimated completion is 2014-10.
What conditions does trial NCT01392326 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT01392326?
The interventions under investigation include: Placebo Comparator (DRUG), Secukinumab (75 mg) (DRUG), Secukinumab (150 mg) (DRUG).
Who is sponsoring clinical trial NCT01392326?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01392326 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.